Renewal Bio Ltd. aims to tackle and solve several of the major health issues that modern societies face: shortage in cells and tissues for transplantation, decreasing fertility and fertility accessibility, degenerative diseases and aging.

Renewal Bio Ltd. is taking a novel approach to generate replacement cell therapy for human regenerative medicine and fertility. Our Research and development team is studying ex-vivo and exutero post-implantation stem cell based embryoid models to understand the basis of gastrulation, organogenesis, and correct organ formation patterns.

Moreover, we are developing a human patient specific stem-cell derived embryoid models (#Stembroids) grown in a controlled patented ex-utero device. We believe that our approach will enable optimizing protocols for human iPSCs differentiation into various mature cell types that can be used afterwards for transplantation to treat or model human diseases and drug studies. Although Renewal Bio is developing a holistic differentiation platform that aims to generate the full repertoire of human cells, our immediate products will focus on three main indications: Hematopoietic stem cells (HSCs) and hepatocyte for blood and liver disorders/disease, respectively, and on oocytes for human infertility problems.